Jerry A Shields
Overview
Explore the profile of Jerry A Shields including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
639
Citations
9502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sener H, Bansal R, Catapano T, Shields J, Shields C
Semin Ophthalmol
. 2024 Nov;
:1-8.
PMID: 39580712
Purpose: To determine the impact of uveal melanoma thickness on patient survival from the date of presentation and at specific time intervals following metastasis-free survival. Methods: In this retrospective cohort...
2.
Shields C, Medina R, Evans H, Valdes-Perez N, Acar A, Bansal R, et al.
Retina
. 2024 Oct;
45(1):1-6.
PMID: 39378373
Purpose: To evaluate the efficacy and safety of high-dose intravitreal topotecan (IvitTopo) for recurrent retinoblastoma. Methods: There were 13 patients with recurrent retinoblastoma treated with high-dose IvitTopo (90 micrograms [...
3.
Bansal R, Sener H, Ganguly A, Shields J, Shields C
Clin Exp Ophthalmol
. 2024 Oct;
53(2):175-183.
PMID: 39364722
Background: Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted...
4.
Tailor P, Kopinski P, DSouza H, Leske D, Olsen T, Shields C, et al.
Ophthalmol Sci
. 2024 Sep;
5(1):100584.
PMID: 39318711
Purpose: To develop and validate machine learning (ML) models to predict choroidal nevus transformation to melanoma based on multimodal imaging at initial presentation. Design: Retrospective multicenter study. Participants: Patients diagnosed...
5.
Yaghy A, Yaghy M, Shields J, Shields C
Semin Ophthalmol
. 2024 Jan;
39(4):289-293.
PMID: 38179986
Large language models (LLMs) show great promise in assisting clinicians in general, and ophthalmology in particular, through knowledge synthesis, decision support, accelerating research, enhancing education, and improving patient interactions. Specifically,...
6.
DeSimone J, Shields C, Kalafatis N, Marous M, Marous C, Shields J, et al.
Clin Dermatol
. 2023 Oct;
42(1):38-45.
PMID: 37866411
A choroidal nevus is a common intraocular tumor in the United States, found in approximately 5% of Caucasian adults. The three main risks of melanocytic choroidal nevus include vision loss...
7.
Shields C, Silva A, Laiton A, Kalafatis N, Schiller E, Lally S, et al.
Clin Dermatol
. 2023 Oct;
42(1):46-55.
PMID: 37858779
Conjunctival melanoma is quite rare, estimated at approximately 0.5 incidence per 1 million persons per year. This malignancy arises from a pre-existing nevus (7%), primary acquired melanosis (74%), or de...
8.
Gonzalez Martinez O, Shields C, Shields J, Chevez-Barrios P, Walley D, Eagle Jr R, et al.
Am J Ophthalmol Case Rep
. 2023 Sep;
32:101912.
PMID: 37680309
Purpose: To report a patient with a unilateral presentation of glaucoma, pain, and acute iris transillumination syndrome simulating iris melanoma. Observations: A 53-year-old male presented with blurred vision and pain...
9.
Shields C, Samuelson A, Oh G, DeSimone J, Sajjadi Z, Bas Z, et al.
Invest Ophthalmol Vis Sci
. 2023 Jul;
64(10):7.
PMID: 37418273
Purpose: To evaluate cumulative incidence of metastasis at specific timepoints after treatment of uveal melanoma in a large cohort of patients and to provide comparison of conditional outcomes in the...
10.
Card K, Barke M, Shields J
Ophthalmology
. 2023 Mar;
130(12):1350.
PMID: 36922338
No abstract available.